Title: Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA
Authors: FEUERECKER BENEDIKTKNORR KARINABEHESHTI ASEIDL C.D'ALESSANDRIA CBRUCHERTSEIFER FRANKTAUBER RRETZ MWEBER WOLFGANGMORGENSTERN ALFREDEIBER MATTHIAS
Citation: NUKLEARMEDIZIN-NUCLEAR MEDICINE vol. 58 no. 2 p. 109
Publisher: SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
Publication Year: 2019
JRC N°: JRC113791
ISSN: 0029-5566 (online)
URI: https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0039-1683483
http://publications.jrc.ec.europa.eu/repository/handle/JRC113791
DOI: 10.1055/s-0039-1683483
Type: Articles in periodicals and books
Abstract: Despite the approval of several new agents metastatic castration resistant prostate cancer is still a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.